BASF advances Nemasphere soybean trait toward 2028 launch

Key highlights
  • Nemasphere soybean varieties are expected in the United States and Brazil from 2028.
  • The trait has peak sales potential of more than €300 million.
  • Field trials showed up to 90% control of key soybean nematodes and average yield gains of up to 10%.
  • Launch varieties will combine Nemasphere with the Enlist E3 soybean trait.

Trait and expected launch

BASF Agricultural Solutions is advancing global commercialization of Nemasphere, a nematode-resistance trait for soybeans. Varieties are expected to be available in the United States and Brazil from 2028. The trait has peak sales potential of more than €300 million.

Performance and market access

Nematodes cause an estimated $4.5 billion in crop losses in Brazil and the United States each season. Nemasphere uses a novel mode of action against key plant-parasitic soybean nematodes, delivering up to 90% control. Field trials showed average yield increases of up to 10%. In Brazil, soybean fields with high root lesion nematode populations also saw yield gains in cotton or corn grown the following season.

EU import authorization for soybeans containing the trait completes the regulatory approvals currently required in key export markets. Planned launch varieties will stack Nemasphere with the Enlist E3 soybean trait, jointly developed and owned by Vylor and M.S. Technologies, L.L.C.

Source: BASF

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

16 November 2026
BASF advances Nemasphere soybean nematode-resistance trait for 2028 launch

Field trials showed up to 90% nematode control and average soybean yield gains of up to 10%.

13 August 2025
BASF, Corteva, and M.S. Technologies to introduce new soybean trait in Brazil by decade's end

New soybean trait combines nematode, herbicide, and insect resistance to boost yields in Brazil, pending regulatory approval and field tests.